Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success | Curated by Alerts360

Nov 4, 2025 - 08:35

0

Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success | Curated by Alerts360

Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints. Stay informed with the latest market updates, stock movements, and financial news to make timely decisions.

Continue Reading

What's Your Reaction?

Like 0

Dislike 0

Love 0

Funny 0

Angry 0

Sad 0

Wow 0

Related Posts

Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies | Curated by Alerts360

Pfizer and Novo Nordisk sweeten offers for Metsera as b...

Nov 4, 2025 0

Bitcoin slips below $100,000 for first time since June. Here’s where it might be headed next. | Curated by Alerts360

Bitcoin slips below $100,000 for first time since June....

Nov 5, 2025 0

Bitcoin falls under $102K: Analysts say BTC is ‘underpriced’ based on fundamentals | Curated by Alerts360

Bitcoin falls under $102K: Analysts say BTC is ‘underpr...

Nov 4, 2025 0

Car sales move into the slow lane. Is the economy downshifting, too? | Curated by Alerts360

Car sales move into the slow lane. Is the economy downs...

Nov 4, 2025 0

If an ex-chancellor pumps crypto and no one notices, does it make a noise? | Curated by Alerts360

If an ex-chancellor pumps crypto and no one notices, do...

Nov 4, 2025 0

10x Research sees shorting Ether as a Bitcoin hedge | Curated by Alerts360

10x Research sees shorting Ether as a Bitcoin hedge | C...

Nov 4, 2025 0